Nothing Special   »   [go: up one dir, main page]

CY1120707T1 - Anti-cd28 εξανθρωπισμενα αντισωματα - Google Patents

Anti-cd28 εξανθρωπισμενα αντισωματα

Info

Publication number
CY1120707T1
CY1120707T1 CY181101006T CY181101006T CY1120707T1 CY 1120707 T1 CY1120707 T1 CY 1120707T1 CY 181101006 T CY181101006 T CY 181101006T CY 181101006 T CY181101006 T CY 181101006T CY 1120707 T1 CY1120707 T1 CY 1120707T1
Authority
CY
Cyprus
Prior art keywords
humanized antibodies
antibodies
receptor
antagonists
inhibiting
Prior art date
Application number
CY181101006T
Other languages
English (en)
Inventor
Caroline Mary
Nicolas Poirier
Bernard Vanhove
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10290080A external-priority patent/EP2361935A1/en
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of CY1120707T1 publication Critical patent/CY1120707T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση αφορά σε εξανθρωπισμένα αντισώματα κατευθυνόμενα έναντι του CD28 υποδοχέα ανθρώπινου λεμφοκυττάρου. Όταν χρησιμοποιούνται σε μονοδύναμη μορφή, αυτά τα αντισώματα είναι ανταγωνιστές, δηλαδή ικανά αναστολής της αλληλεπίδρασης CD28/B7, χωρίς ενεργοποίηση CD28. Αυτά τα αντισώματα μπορούν να χρησιμοποιούνται ιδιαιτέρως ως θεραπευτικοί παράγοντες για αναστολή ενεργοποίησης Τ κυττάρου μέσω του υποδοχέα CD28.
CY181101006T 2010-02-18 2018-09-28 Anti-cd28 εξανθρωπισμενα αντισωματα CY1120707T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10290080A EP2361935A1 (en) 2010-02-18 2010-02-18 Anti-CD28 humanized antibodies
EP10290389 2010-07-13
PCT/IB2011/050646 WO2011101791A1 (en) 2010-02-18 2011-02-16 Anti-cd28 humanized antibodies
EP11707918.6A EP2536764B1 (en) 2010-02-18 2011-02-16 Anti-cd28 humanized antibodies

Publications (1)

Publication Number Publication Date
CY1120707T1 true CY1120707T1 (el) 2019-12-11

Family

ID=44482493

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101006T CY1120707T1 (el) 2010-02-18 2018-09-28 Anti-cd28 εξανθρωπισμενα αντισωματα

Country Status (16)

Country Link
US (3) US8785604B2 (el)
EP (2) EP3428192B1 (el)
JP (1) JP5992340B2 (el)
CA (1) CA2788544C (el)
CY (1) CY1120707T1 (el)
DK (1) DK2536764T3 (el)
ES (2) ES2680570T3 (el)
HR (1) HRP20181360T1 (el)
HU (1) HUE039677T2 (el)
LT (1) LT2536764T (el)
PL (1) PL2536764T3 (el)
PT (1) PT2536764T (el)
RS (1) RS57667B1 (el)
SI (1) SI2536764T1 (el)
TR (1) TR201811185T4 (el)
WO (1) WO2011101791A1 (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210902A1 (en) * 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
EP3428192B1 (en) 2010-02-18 2021-08-11 OSE Immunotherapeutics Anti-cd28 humanized antibodies
WO2014120916A1 (en) * 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
EP3077415B1 (en) 2013-12-06 2020-02-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28
LT3390450T (lt) * 2015-12-15 2021-06-25 Ose Immunotherapeutics Antii-cd28 humanizuoti antikūnai, paruošti vartoti žmonėms
AR108975A1 (es) 2016-07-06 2018-10-17 Celgene Corp Anticuerpos con baja inmunogenicidad y sus usos
JP2019522486A (ja) 2016-07-13 2019-08-15 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗原提示細胞模倣足場およびそれを作製および使用するための方法
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3796934A4 (en) * 2018-05-23 2022-04-06 Manysmart Therapeutics, Inc. BISPECIFIC T-CELL ENGAGER AND USES THEREOF
EP3806848A2 (en) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
JP2023538891A (ja) 2020-08-19 2023-09-12 ゼンコア インコーポレイテッド 抗ｃｄ２８組成物
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
KR20240109604A (ko) 2021-09-03 2024-07-11 고 테라퓨틱스, 인크. 항-글리코-cMET 항체 및 그의 용도
CA3230933A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
EP4423248A1 (en) 2021-10-28 2024-09-04 Lyell Immunopharma, Inc. Methods of generating cells
WO2023114701A2 (en) * 2021-12-13 2023-06-22 BioLegend, Inc. Cd28 binding antibodies and antigen binding fragments thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
BR0116686A (pt) * 2000-12-14 2003-12-30 Fujisawa Pharmaceutical Co Anticorpos anti-cd28 silenciados e uso dos mesmos
PT1345969E (pt) * 2000-12-26 2010-11-17 Inst Nat Sante Rech Med Anticorpos anti-cd28
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
TW200732350A (en) * 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
ME02396B (me) * 2008-07-18 2016-08-31 Bristol Myers Squibb Co Smješe monovalentne za vezivanje sa cd28 i metodi upotrebe
MX2011006621A (es) * 2008-12-19 2011-07-12 Novartis Ag Polipeptidos solubles para uso en el tratamiento de trastornos autoinmunes e inflamatorios.
EP2210902A1 (en) 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
EP3428192B1 (en) * 2010-02-18 2021-08-11 OSE Immunotherapeutics Anti-cd28 humanized antibodies
LT3390450T (lt) * 2015-12-15 2021-06-25 Ose Immunotherapeutics Antii-cd28 humanizuoti antikūnai, paruošti vartoti žmonėms

Also Published As

Publication number Publication date
ES2680570T3 (es) 2018-09-10
US20170114136A1 (en) 2017-04-27
CA2788544C (en) 2019-03-05
JP2013519389A (ja) 2013-05-30
RS57667B1 (sr) 2018-11-30
US20130078236A1 (en) 2013-03-28
US20150071916A1 (en) 2015-03-12
EP2536764B1 (en) 2018-07-04
SI2536764T1 (sl) 2018-11-30
PL2536764T3 (pl) 2018-12-31
EP3428192B1 (en) 2021-08-11
EP2536764A1 (en) 2012-12-26
CA2788544A1 (en) 2011-08-25
HUE039677T2 (hu) 2019-01-28
US10364287B2 (en) 2019-07-30
LT2536764T (lt) 2018-10-25
JP5992340B2 (ja) 2016-09-14
WO2011101791A1 (en) 2011-08-25
US8785604B2 (en) 2014-07-22
HRP20181360T1 (hr) 2018-11-02
PT2536764T (pt) 2018-08-10
US9562098B2 (en) 2017-02-07
EP3428192A1 (en) 2019-01-16
ES2896149T3 (es) 2022-02-24
TR201811185T4 (tr) 2018-08-27
DK2536764T3 (en) 2018-09-17

Similar Documents

Publication Publication Date Title
CY1120707T1 (el) Anti-cd28 εξανθρωπισμενα αντισωματα
CY1119760T1 (el) Χρηση τ κυτταρων τροποποιημενων απο χιμαιρικο υποδοχεα αντιγονου για τη θεραπευτικη αγωγη καρκινου
CY1123145T1 (el) Anti-cd40 αντισωματα
CY1122278T1 (el) Αντι il-36r αντισωματα
CY1120297T1 (el) Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων
CY1120637T1 (el) Πολυπεπτιδικα αντισωματα που ανταγωνιζονται cd40
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EA202192165A1 (ru) Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы
EA201391059A1 (ru) Композиции для лечения рака и способы их применения
EA201491573A1 (ru) Применение передающего сигнал домена cd2 в химерных антигенспецифических рецепторах второго поколения
EA201170475A1 (ru) Иммунотерапевтические средства против комплекса tcr
AR093788A1 (es) Inmunoterapia con agentes de enlace
EP2331136A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
CR20140312A (es) 4-fenil-piridinas sustiuidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
EA201391764A1 (ru) Агонисты рецептора glp-1/глюкагона длительного действия
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
NZ604510A (en) Dilutable biocidal compositions and methods of use
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
TR201903403T4 (tr) İmmünoglobulin preparatı.